Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
REseau NAtional de Rpe interDisciplinaire · Centre Hospitalier René-Dubos · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
603
total citations
- FWCI
- 27.74
- Percentile
- 100%
- References
- 24
Citations per year
Authors
21- JDJ.-Y. DouillardCorresponding
REseau NAtional de Rpe interDisciplinaire, Centre Hospitalier René-Dubos
- SSSalvatore Siena
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
- JCJ Cassidy
Beatson West of Scotland Cancer Centre
- JTJosep Tabernero
Vall d'Hebron Hospital Universitari
- RLRonald L. Burkes
Mount Sinai Hospital
Topics & keywords
Topics
Keywords
- Medicine
- Panitumumab
- KRAS
- Internal medicine
- Hazard ratio
- Colorectal cancer
- Clinical endpoint
- Randomized controlled trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.